Cargando…

Prognostic Mutational Signatures of NSCLC Patients treated with chemotherapy, immunotherapy and chemoimmunotherapy

Different types of therapy are currently being used to treat non-small cell lung cancer (NSCLC) depending on the stage of tumor and the presence of potentially druggable mutations. However, few biomarkers are available to guide clinicians in selecting the most effective therapy for all patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Margaret R., Wang, Yuezhu, D’Agostino, Ralph, Liu, Yin, Ruiz, Jimmy, Lycan, Thomas, Oliver, George, Miller, Lance D., Topaloglu, Umit, Pinkney, Jireh, Abdulhaleem, Mohammed N., Chan, Michael D., Farris, Michael, Su, Jing, Mileham, Kathryn F., Xing, Fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042886/ https://www.ncbi.nlm.nih.gov/pubmed/36973365 http://dx.doi.org/10.1038/s41698-023-00373-0

Ejemplares similares

Use of comprehensive genomic profiling for biomarker discovery for the management of non-small cell lung cancer brain metastases
por: Abdulhaleem, Mohammed, et al.
Publicado: (2023)

c-Met Mediated Cytokine Network Promotes Brain Metastasis of Breast Cancer by Remodeling Neutrophil Activities
por: Liu, Yin, et al.
Publicado: (2023)

SMARCA4 mutations in KRAS‐mutant lung adenocarcinoma: a multi‐cohort analysis
por: Liu, Liang, et al.
Publicado: (2020)

Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
por: Cortellini, Alessio, et al.
Publicado: (2022)

TCR Coexpression Signature Predicts Immunotherapy Resistance in NSCLC
por: Wang, Yuntao, et al.
Publicado: (2022)

A Review on Cancer Immunotherapy and Applications of Nanotechnology to Chemoimmunotherapy of Different Cancers
por: Akkın, Safiye, et al.
Publicado: (2021)

Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer
por: Hughes, Ryan T, et al.
Publicado: (2023)

The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma
por: Wilson, Harper L., et al.
Publicado: (2020)

Prevalence of DNA Repair Gene Mutations in Blood and Tumor Tissue and Impact on Prognosis and Treatment in HNSCC
por: Burcher, Kimberly M., et al.
Publicado: (2021)

Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer
por: Chen, Hualin, et al.
Publicado: (2022)

Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
por: Burcher, Kimberly M., et al.
Publicado: (2021)

Neoadjuvant chemoimmunotherapy as a potential therapeutic option in NSCLC UICC stage IIIA with multilevel N2 disease
por: Menghesha, Hruy, et al.
Publicado: (2022)

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2021)

Perioperative Outcomes of Video-Assisted Thoracoscopic Surgery Versus Open Thoracotomy After Neoadjuvant Chemoimmunotherapy in Resectable NSCLC
por: Zhang, Baihua, et al.
Publicado: (2022)

The predictive role of hematologic markers in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy: a retrospective cohort study
por: Liu, Wenliang, et al.
Publicado: (2023)

Chemoimmunotherapy in advanced esophageal squamous cell carcinoma: optimizing chemotherapy regimens for immunotherapy combinations
por: Liu, Zhichao, et al.
Publicado: (2022)

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
por: Laza‐Briviesca, Raquel, et al.
Publicado: (2021)

The utilization of immunotherapy with radiation therapy in lung cancer: a narrative review
por: Heinzerling, John H., et al.
Publicado: (2021)

Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms
por: Liu, Zhichao, et al.
Publicado: (2022)

Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC
por: Wang, Zemin, et al.
Publicado: (2022)

Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma
por: He, Xiran, et al.
Publicado: (2020)

Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma： A Retrospective Study
por: Xiao, Yi, et al.
Publicado: (2022)

Immune-Related Gene Signatures to Predict the Effectiveness of Chemoimmunotherapy in Triple-Negative Breast Cancer Using Exploratory Subgroup Discovery
por: Kholod, Olha, et al.
Publicado: (2022)

Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis
por: Jiang, Juan, et al.
Publicado: (2022)

MAPK signaling regulates the efficacy of chemoimmunotherapy
por: Ghiringhelli, François
Publicado: (2022)

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2022)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Goodness-of-fit techniques
por: D'Agostino, Ralph, et al.
Publicado: (1986)

Dual roles for immune metagenes in breast cancer prognosis and therapy prediction
por: Alistar, Angela, et al.
Publicado: (2014)

Baseline tumor gene expression signatures correlate with chemoimmunotherapy treatment responsiveness in canine B cell lymphoma
por: Dittrich, Katherine, et al.
Publicado: (2023)

Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy
por: Chen, Chian-Wei, et al.
Publicado: (2023)

Chemoimmunotherapy as long-term maintenance therapy for cancer
por: Egilmez, Nejat K., et al.
Publicado: (2012)

Complete response of metastatic gastric cancer to chemoimmunotherapy
por: Ina, Kenji, et al.
Publicado: (2017)

Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy
por: Wang, Tianqi, et al.
Publicado: (2021)

Targeted delivery of liposomal chemoimmunotherapy for cancer treatment
por: Liu, Yusheng, et al.
Publicado: (2022)

Pleurodesis and Immunotherapy in NSCLC; Medical Thoracoscopy or VATS?
por: Zarogoulidis, Paul, et al.
Publicado: (2020)

Recent Advances in Immunotherapy in Metastatic NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Immunotherapy and NSCLC: The Long and Winding Road
por: Rossi, Antonio
Publicado: (2020)

Immunotherapy in NSCLC Patients with Brain Metastases
por: Buriolla, Silvia, et al.
Publicado: (2022)

Cryobiopsy for pneumonitis diagnosis in NSCLC immunotherapy
por: Zarogoulidis, Paul, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u0kg3ccv0613aafb0ivuphb230